GTG secures new BREVAGen contracts
Genetic Technologies (ASX:GTG) has announced that up to six new US breast centres will start offering the company’s BREVAGenplus breast cancer risk assessment tool this calendar quarter.
The company expects a number of new breast diagnosis, imaging and treatment centres to pick up the test later the year, and so is anticipating an acceleration of sales growth starting in the second half.
Genetic Technologies recently completed a restructuring of its operations that involved selling its Australian genetics business and refocusing on sales to large comprehensive breast treatment and imaging centres.
BREVAGenplus launched in October. It is an upgraded version of the company’s BREVAGen test that is compatible with black and Hispanic women as well as Caucasians.
Genetic Technologies separately revealed that non-executive director David Carter has passed away.
“Our company is deeply saddened by the early passing of Mr David Carter,” Genetic Technologies said in a statement. “David will always be remembered fondly and we feel privileged to have had the pleasure of working with such a learned and warm person.”
Genetic Technologies (ASX:GTG) shares were trading 108.3% higher at $0.025 as of around 1 pm on Friday.
High doses of fertility drug linked to pregnancy risks
High doses of clomiphene citrate, accumulated over multiple fertility treatment cycles, could...
Bird flu vaccine to be rolled out to "priority" species
The Australian Government has announced the imminent rollout of a vaccine to protect some of...
Top 6 artificial sweeteners associated with accelerated brain aging
An eight-year study tracking brain health of 12,772 Brazilian adults has associated six sugar...
